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ORIGINAL ARTICLE
Intrathecal Morphine Remotely Preconditions the
Heart Via a Neural Pathway
Gordon Tin Chun Wong, MBBS,* Lu Yao, MD,*† Zhengyuan Xia, MD, PhD,* and
Michael G. Irwin, MD*AU1
Abstract: Central opioid receptor activation triggers cardioprotection
against ischemia reperfusion injury, independent of peripheral opioid
receptor activity. Using a rodent model of myocardial ischemia
reperfusion injury with infarct size as the primary outcome, we tested
the hypothesis that spinal opioids confer this beneficial effect via
a neural pathway. Intrathecal morphine reduced the infarct size
compared with control (23% ± 7% vs. 58% ± 3%, respectively,
P , 0.01). Prior antagonism of the autonomic pathway, and the
receptors for bradykinin, calcitonin gene–related peptide, and the
KATP channel, respectively, abolished this cardioprotection (54%
± 13%, 52% ± 10%, 56% ± 9%, and 49% ± 8%, respectively,
P , 0.05). In a second set of experiments, we demonstrated that the
increased expression of myocardial phosphorylated-Akt and
endothelial nitric oxide synthase induced by intrathecal morphine
was blocked by prior administration of hexamethonium. These find-
ings support the notion that spinal opioid receptors stimulate a neural
pathway that uses nonopioid neurotransmitters to confer cardioprotec-
tion from ischemia reperfusion injury. The use of intrathecal morphine
for this purpose has potential clinical application, and it is already
being used in the perioperative period to provide prolonged analgesia.
Key Words: opioids, intrathecyal morphine, cardiac protection, pre-
conditioning, ischemia reperfusion injuryAU3
(J Cardiovasc Pharmacol 2012;0:1–7)
INTRODUCTION
Remote triggers of cardioprotection have been the
subject of great research interest as access to the coronary
circulation is not necessary to confer benefits. The protective
maneuver may be effective when applied before, during, and
immediately after the ischemic event and include triggers
such as intermittent ischemia applied to organs remote to the
heart or administration of pharmacological agents.1,2 Fortu-
itously, some of the agents capable of cardioprotection are
already used clinically for other reasons, such as opioid anal-
gesics. We have previously demonstrated that the activation
of spinal opioid receptors by morphine is an effective means
of remotely protecting the heart.3,4 This protection occurs
independent of activation of peripheral opioid receptors.
More recently, Gross et al5 confirmed the importance of cen-
tral mu opioid receptors in cardioprotection. This mode of
remote preconditioning is of potential significance in the peri-
operative setting as neuroaxial anesthesia is often performed
with the administration of intrathecal morphine to provide
postoperative analgesia.
Bradykinin produced by sympathetic nerve endings6 is
released during myocardial ischemia.7,8 This kinin has pre-
viously been implicated in the mechanism of remote ischemic
cardiac preconditioning involving a neural pathway.9 It also
causes a paracrine release of neurotransmitters such as calci-
tonin gene–related peptide (CGRP) from C sensory nerve
endings.10 CGRP has also been demonstrated to mediate
remote ischemic preconditioning.11 Intense research efforts
have been devoted to elucidating the mechanisms of cardio-
protection, with elements being identified at the subcellular
levels that are common to different triggers and modes of
cardioprotection. In particular, the phosphatidylinositol-
3-kinase nitric oxide pathway (PI3K–Akt–eNOS) has been
identified to be activated in cardioprotection triggered by
insulin,12 corticosteroids,13 and bradykinin,14 among others.
This pathway also has a role in ischemic postconditioning,15
and in mediating the antiapoptotic effects of hypoxic precon-
ditioning in cardiomyocytes.16 This and other pathways may
converge on the mitochondrial KATP channels and the mito-
chondrial permeability transition pore for its final effect.17
We hypothesized that intrathecal morphine produces its
cardioprotective properties via the activation of a neural
pathway, requiring the activation of bradykinin and CGRP
receptors and the involvement of the PI3K–Akt–eNOS
pathway and the KATP channel.
METHODS
This study protocol was approved by our institutional
animal ethics committee, and the procedures were conducted
in accordance with the NIH Animal Research Advisory
Committee guidelines. Male Sprague–Dawley rats, weighing
300 ± 25 g were used. They were given free access to food
and water, exposed to 12-hour light and dark cycles, and were
housed in separate cages before experimentation (F F1ig. 1
AU4
).
Surgical Procedures
The rats were anesthetized by an intraperitoneal injection
of pentobarbitone (50 mg/kg of body weight). After sterile
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preparation of the posterior neck with 70% ethanol, a small
polyethylene-10 catheter (4 cm; Smiths Medical International
Ltd, United Kingdom) was inserted through an opening in the
atlanto-occipital membrane to the thoracic spinal cord according
to the method of Yaksh and Rudy.18 The wound was closed
with deep, followed by cutaneous, interrupted sutures. After
emergence from anesthesia, these animals were examined for
any gross motor or sensory deficits. They were provided with
analgesia for the 3 days after surgery with meloxicam 2 mg/kg
orally. Those animals demonstrating any neurological deficits
were excluded from further experimentation. In addition, after
finishing the experiment, Evan blue dye was injected through
the intrathecal catheter to determine catheter location and any
damage to the spinal cord.
After a minimum of 3 days after intrathecal catheter
placement, the rats were reanesthetized by intraperitoneal
administration of pentobarbitone (50 mg/kg of body weight)
maintained by repeat doses of 25 mg/kg every 60–90 minutes
as necessary. All the animals underwent tracheotomy and tra-
cheal intubation. Mechanical ventilation was provided with
a Harvard Apparatus Rodent Respirator (Harvard Apparatus,
Boston, MA), and the rats were ventilated with room air at 70–
80 breaths per minute. Body temperature was monitored and
maintained at 37 ± 18C (mean ± SD) using a heating pad. The
femoral artery was cannulated for direct blood pressure mon-
itoring via a pressure transducer and a lead-II electrocardio-
gram monitored heart rate (HR) via subcutaneous stainless
steel electrodes connected to a PowerLab monitoring system
(ML750 PowerLab/4sp with MLT0380 Reusable BP
Transducer; AD Instruments, Colorado Springs, CO). Hemo-
dynamic values including HR and mean arterial blood pressure
(MAP) were recorded at baseline, at the end of the treatment
period, at the end of the ischemic and reperfusion periods,
respectively, for comparison. The right femoral vein was can-
nulated for saline infusion. A left thoracotomy was performed
to expose the heart at the fifth intercostal space. After removing
the pericardium, a 6-0 Prolene loop, along with a snare
occluder, was encircled around the origin of the left coronary
artery in preparation for inducing ischemia reperfusion injury.
After surgical preparation, the rats were allowed to stabilize for
15 minutes before drug administration.
Drug Protocols
The rats were assigned to 1 of 10 treatment groups
according to a computer generated randomized sequence:
control group (CON) received intrathecal administration of
30 mL normal saline (saline vehicle); the morphine group
(MPC) received intrathecal morphine at a total dose of
3 mg/kg (morphine sulfate injection BP, David Bull Labora-
tory, Hong Kong). This morphine dose was chosen on the
basis of a previous dose response study.19 The solutions were
administered by way of 3 consecutive 5-minute infusions
interspersed with 5-minute infusion free periods. This pattern
of alternating drug administration with a drug-free period was
done to mimic the pattern of ischemic preconditioning.
Fifteen minutes before intrathecal morphine infusions, differ-
ent antagonists were given via the intravenous route in
respective groups to evaluate the effects that blocking the
autonomic pathway, KATP channels, CGRP receptors or bra-
dykinin receptors, have on morphine preconditioning. Simi-
larly, the same chemicals were given 15 minutes before
intrathecal saline infusions to evaluate for any intrinsic effects
that each of the chemicals may have had on infarct size (IS).
Therefore, groups of animals (n = 6 per group) were given,
respectively, 0.01 nmole/kg of CGRP fragment 8–37,11
300 mg/kg of the bradykinin B2 antagonist HOE-140,
9
20 mg/kg of the nicotinic receptor blocker hexamethonium
bromide (HEX)9,20 or 0.3 mg/kg of glibenclamide (GLI)21
before either saline or morphine infusions. The doses chosen
were sufficient to overcome the effects of remote precondi-
tioning in previous studies. Immediately after the drug pro-
tocol, 30 minutes of ischemia was induced in the territory
supplied by the left coronary artery by pulling the snare tight
and securing the threads with a mosquito hemostat. Ischemia
was confirmed by electrocardiographic changes, a substantial
decrease in mean arterial pressure, and cardiac cyanosis. The
rats were omitted from further data analysis if severe hypo-
tension (arterial mean blood pressure ,30 mm Hg) or intrac-
table ventricular fibrillation occurred. Where this occurred,
the subsequent rat received the same treatment as the
deceased rat and thereafter the computer sequence was fol-
lowed. The ischemia period was followed by 120 minutes of
reperfusion. The hearts were then excised, and the IS as a per-
centage of the area at risk (IS/AAR) was determined by
triphenyltetrazolium and Evan Blue staining.
Infarct Size Determination
The hearts were excised and transferred to a Langendorff
apparatus on completion of the reperfusion period and
immediately perfused with normal saline for 1 minute at
a pressure of 100 cm H2O to flush out residual blood. The
snare was securely retightened and 0.25% Evan blue dye
injected to stain the normally perfused region of the heart. This
procedure allowed visualization of the normal, nonischemia
region, and the AAR. The hearts were then frozen and cut into
2-mm slices. Thereafter, the slices were stained by incubation
at 378C for 20 minutes in 1% 2,3,5-triphenyltetrazolium
(Sigma Chemical Co) in phosphate buffer at pH 7.4. This
was followed by immersion in 10% formalin for 20 minutes
to enhance the contrast of the stain. The areas of infarct and
risk zone for each slice were traced and digitized using
FIGURE 1. Treatment protocols. CGRP8–37, a selective CGRP
receptor antagonist; CON, control; GLI, glibenclamide, a non-
selective KATP channel blocker; HEX, hexamethonium, an auto-
nomic ganglion blocker; HOE-140, a selective bradykinin B2
receptor antagonist; MPC, intrathecal morphine preconditioning.
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a computerized planimetry technique (SigmaScan 4.0, Systat
Software Inc, Richmond, CA). The volumes of the left ven-
tricles, IS, and AAR were calculated by multiplying each area
with slice thickness and summing the product. The infarct was
expressed as a percentage of the AAR (IS/AAR) and this ratio
was used to compare the differences among the groups.
Tunel Staining for Apoptosis
Heart samples were collected from the left ventricular
ischemic area in 3 separate groups immediately after reperfu-
sion for tunel staining, using a proprietary kit (In Situ Cell
Death Detection Kit, Roche Biochemicals, Mannheim,
Germany). The 3 groups consisted of a sham group that
underwent all surgical procedures and infusion of saline but
without the induction of ischemia reperfusion injury; a CON
that received saline and ischemia reperfusion injury, a mor-
phine preconditioning group (n = 3). The tissue was fixed
with formalin, embedded in paraffin, and 4-mm thick sections
were incubated with proteinase K (20 mg/mL) and then with
terminal deoxynucleotidyl transferase. After washing, antidi-
goxigenin conjugate and peroxidase substrate were applied to
the sections. Finally, they were counterstained with hematox-
ylin. For each section, 10 random fields were examined under
a Nikon light microscope (·400 magnification).
Protein Extraction and Western Blotting Analysis
The involvement of total Akt, total eNOS, phosphory-
lated-Akt (p-Akt) and phosphorylated-eNOS (p-eNOS) was
evaluated in a second set of experiment consisting of 5 groups
(n = 3): a sham group that underwent all surgical procedures
and infusion of saline but without the induction of ischemia
reperfusion injury; a CON that received saline and ischemia
reperfusion injury, a morphine preconditioning group, a group
receiving hexamethonium and 1 group receiving hexametho-
nium before intrathecal morphine. Heart tissue samples were
collected after reperfusion, respectively, from the ischemic
left ventricle regions for evaluation of total eNOS, total
Akt, p-Akt, and p-eNOS content. The collected samples were
immediately frozen at 2808C until further processing. The
frozen tissues in groups were powdered and homogenized
in lysis buffer containing 20 mM Tris–HCl (pH 7.5),
50 mM 2-mercaptoethanol, 5 mM ethylene glycol tetraacetic
acid, 2 mM ethylenediaminetetraacetic acid, 10 mM NaF,
1 mM phenylmethylsulfonyl fluoride, 25 mg/mL leupeptin,
2 mg/mL aprotinin, 0.1% NP40, 0.1% sodium dodecyl sul-
fate, 0.1% deoxycholic acid for protein extraction. The
homogenate was centrifuged at 10,000g to separate debris
and supernatant, and then the concentrations of proteins in
the supernatant were determined by Bradford protein assay.
Equal amounts of protein (60 mg) from each group were
separated by 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred to PVDF membrane for
1 hourAU5 . The membranes then were blocked in 5% skimmed
milk for 1 hour and incubated in 1:1000 dilution of anti-
p-Akt, anti-eNOS, and anti-GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) antibodies (Cell Signaling
Technology Inc, MA) and incubated overnight at 48C. The
membranes were then washed and incubated with antirabbit
IgG (Cell Signaling Technology Inc) conjugated to
horseradish peroxidase (1:10,000) for 1 hour. Protein bands
were detected by a standard ECL method and images were
measured by means of a densitometer with analysis software.
Statistics
Previous work performed in our laboratory using the
same model of cardiac ischemia reperfusion injury3,19 indicated
the expected IS/AAR of the CON to be between 50% and 65%
and the magnitude of IS/AAR reduction to be at least 50%.
Therefore, 5 animals per group would be required to give
a power of 80% and a P value of 0.05. Data are expressed
as mean ± SD and data analysis was performed with a personal
computer statistical software package (Prism v4.0; GraphPad
Software, San Diego, CA). Data were analyzed between
groups using analysis of variance with a Student–Newman–
Keuls post hoc test for multiple comparisons. For the hemo-
dynamic data, a 2-factor mixed design analysis of variance
with repeated measure on time was used for analysis performed
by SPSS v16 for Windows. Statistical differences were consid-
ered significant if the P value was ,0.05.
RESULTS
A total of 94 rats were used for the study. Three rats were
excluded because of neurological damage after intrathecal
catheter insertion. A further 7 did not complete the ischemia
reperfusion protocol becomes of severe hypotension or ven-
tricular fibrillation. There was 1 each from the CON, GLI,
MPC, CGRP8–37 + MPC, HEX + MPC and 2 from HEX
group. A total of 84 rats completed the study, all had the correct
position of the intrathecal catheters confirmed at necropsy, and
none had obvious macroscopic damage to the spinal cord.
The hemodynamic parameters are shown in T T1able 1.
There were no significant differences between each of the
groups when compared with the CON for each time point.
As expected, myocardial ischemia resulted in a substantial
drop in MAP across all the groups.
The IS in the CON was (58% ± 3%) The sole adminis-
tration of the antagonist compounds before ischemia reperfusion
did not alter ISs compared with the CON (F F2ig. 2). Intrathecal
morphine significantly reduced the IS compared with control
(23% ± 7%, P, 0.01). However, this effect was abolished with
the prior administration of CGRP8–37, HOE-140, hexametho-
nium or GLI. Intrathecal morphine also reduced the number of
apoptotic cells compared with control (F F3ig. 3).
Phosphorylated-Akt (pAkt) expression was comparable
between the sham, control, and morphine preconditioning
groups at reperfusion. Intrathecal morphine preconditioning
significantly increased the level of pAkt expressed after
reperfusion (F F4ig. 4). The levels of eNOS decreased after
ischemia reperfusion injury in the CON compared with the
sham but morphine preconditioning was able to attenuate this
decrease, restoring the levels to that of the sham group (F F5ig. 5).
DISCUSSION
In this study, we delineated the major aspects of
intrathecal morphine mediated cardioprotection. In addition
to demonstrating the antiinfarct effects of intrathecal mor-
phine preconditioning, these results support our hypothesis
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that spinal opioid receptor activation, at least in part, uses a
neural pathway to confer cardioprotection. We further
demonstrated that this pathway involves bradykinin and
CGRP receptors and invokes the PI3K–AKT–eNOS pathway
and, consequently, the opening of the KATP channels. Ulti-
mately this chain of events results in a reduction of cardiac
myocyte apoptosis. This process may be abolished with the
prior administration of hexamethonium with changes in eNos
and pAkt expression similar to control.
Pharmacological modes of cardioprotection, such as
remote cardioprotection from ischemic preconditioning or
postconditioning, circumvent the limitation of having to
access the coronary circulation to induce protection. Systemic
and intrathecal opioids are known to be cardioprotective in
experimental models,22,23 with the latter mode of delivery
being a form of remote cardioprotection.3,4 Endothelial nitric
oxide synthase has been shown to be associated with myo-
cardium protection triggered by a number of different
ligands.24 In particular, it is the increased phosphorylation
of the eNos–Ser1177 site that accounts for the beneficial
effects.12 The KATP channel have long been suggested as
one of the end effectors of ischemic preconditioning, with
its opening during ischemia conferring benefits to the ische-
mic cell.25 Therefore, although not novel, the data
TABLE 1. Hemodynamic Parameters (Mean ± SD)
Group n
Baseline Treatment Ischemia Reperfusion
HR MAP HR MAP HR MAP HR MAP
CON 6 399 ± 28 111 ± 16 390 ± 19 103 ± 17 360 ± 26 81 ± 16 355 ± 23 89 ± 9
CGRP8–37 6 393 ± 31 99 ± 19 381 ± 27 93 ± 17 355 ± 16 69 ± 17 355 ± 21 87 ± 15
HOE-140 6 397 ± 22 107 ± 14 385 ± 17 93 ± 11 356 ± 18 73 ± 10 347 ± 16 86 ± 7
HEX 6 403 ± 26 103 ± 23 384 ± 22 82 ± 21 356 ± 17 80 ± 15 357 ± 14 86 ± 13
GLI 6 389 ± 46 102 ± 21 376 ± 41 99 ± 18 341 ± 39 71 ± 10 337 ± 33 85 ± 9
MPC 6 388 ± 23 103 ± 24 380 ± 20 96 ± 19 343 ± 29 73 ± 11 352 ± 32 86 ± 16
CGRP8–37 + MPC 6 388 ± 18 96 ± 28 380 ± 19 92 ± 22 348 ± 31 68 ± 14 343 ± 32 84 ± 11
HOE-140 + MPC 6 394 ± 30 102 ± 13 391 ± 36 86 ± 15 354 ± 37 70 ± 11 343 ± 34 82 ± 9
HEX + MPC 6 397 ± 23 108 ± 16 371 ± 22 80 ± 12 361 ± 11 73 ± 11 361 ± 17 87 ± 9
GLI + MPC 6 386 ± 26 98 ± 21 374 ± 24 96 ± 17 348 ± 19 77 ± 6 342 ± 28 85 ± 7
CGRP8–37, a selective CGRP receptor antagonist; GLI = glibenclamide, a nonselective KATP channel blocker; HEX, hexamethonium, an autonomic ganglion blocker; HOE-140,
a selective bradykinin B2 receptor antagonist; MPC = intrathecal morphine preconditioning.
FIGURE 2. Infarct sizes. CGRP8–37, a selective CGRP receptor
antagonist; GLI = glibenclamide, a nonselective KATP channel
blocker; HEX = hexamethonium, an autonomic ganglion
blocker; HOE-140, a selective bradykinin B2 receptor antago-
nist; MPC = intrathecal morphine preconditioning. *P , 0.05
versus control; †P , 0.05 versus MPC.
FIGURE 3. Antiapoptotic effect of intrathecal morphine. Top
panel: representative pictures for tunel stain of sections. Bot-
tom panel: tunel cell positive counts per high power field;
MPC = intrathecal morphine preconditioning; #P , 0.01 ver-
sus Sham; *P , 0.01 versus CON.
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nevertheless show that pharmacological manipulation of spi-
nal opioid receptors can activate these salvage mechanisms in
the myocyte. Of particular interest are the implications of this
to the understanding of remote preconditioning signaling.
In support of a neural pathway of transmission, Gho
et al26 have demonstrated that remote ischemic preconditioning
can be abolished with the use of hexamethonium. More
recently, a novel mode of remote preconditioning has been
demonstrated whereby stimulation of small pain fibers resulted
in cardioprotection, a phenomenon that can be abolished by
transection of the spinal cord. In that study, the authors pro-
posed that the nociceptive signals trigger a dorsal root reflex
and activation of the cardiac sympathetic nervous system that
ultimately leads to cardioprotection.20 Interestingly, this neural
circuit can be interrupted by the administration of bradykinin
and CGRP antagonists. Our results, when interpreted in the
light of this study, seem to suggest that activation of central
receptors by intrathecal morphine triggers a neural response
that similarly involves CGRP and bradykinin receptors. More-
over, it is possible that intrathecal morphine activates the same
FIGURE 4. Total Akt and p-Akt
protein expression. A, Representa-
tive Western Blot images. B, Total
Akt expression as a percentage of
sham. C, Phosphorylated-Akt as
percentage of sham. Akt, = ser-
ine/threonine protein kinase (also
known as protein kinase B); GADPH,
glyceraldehyde-3-phosphate
dehydrogenase; HEX = Hexametho-
nium; MPC, intrathecal morphine
preconditioning; pAkt = phosphor-
ylated Akt; #P , 0.05 versus Sham;
*P , 0.01 versus CON; †P , 0.01
versus MPC.
FIGURE 5. Total eNOS and p-eNOS
protein expression. A, Representa-
tive Western Blot images. B, Total
eNOS. C, Phosphorylated eNOS.
CON = control; eNOS = endothelial
nitric oxide synthase; MPC =
intrathecal morphine precondition-
ing; GADPH = glyceraldehyde-
3-phosphate dehydrogenase; p-
eNOS = phosphorylated endothelial
nitric oxide synthase. #P , 0.05 ver-
sus Sham; *P , 0.01 versus CON;
†P , 0.01 versus MPC.
J Cardiovasc Pharmacol  Volume 0, Number 0, Month 2012 Intrathecal Morphine Cardioprotection
 2012 Lippincott Williams & Wilkins www.jcvp.org | 5
efferent component of the neural arc. This morphine-activated
pathway similarly can be blocked by hexamethonium, imply-
ing that the signals are conveyed along autonomic fibers as is
the case with remote ischemic preconditioning and remote
preconditioning of trauma. The signals lead to the release of
bradykinin and CGRP that triggers the cascade of intracellular
events that result in the cardioprotective effect. Thus, in this
study, we have demonstrated that activation of spinal opioid
receptors can activate the PI3K–Akt, eNOS pathway in the
myocardium similar to that produced by direct receptor activa-
tion by systemic ligands. A further implication is that the
efferent impulses may not be confined to the segments that
innervate the heart. It is possible that its benefits may spread
beyond that of cardioprotection. Interestingly, limb ischemia
has been shown in to be protective for both the heart and lung
in an animal model of cardiopulmonary bypass.27
Results from laboratory studies into signaling pathways
of remote preconditioning tend to promote one mode of signal
transmission as being responsible to the exclusion of other
modes. However, evidence exists to support multiple means
via which the message is conveyed to the heart in remote
ischemic preconditioning, including neural and humoral path-
ways.28 Remote ischemic preconditioning may also induce
systemic anti-inflammatory and antiapoptotic responses that
may contribute to the protection.29,30 Although this study dem-
onstrated a neural component to the transmission of signals
from intrathecal morphine, other mechanisms may concur-
rently contribute to the cardioprotective effects. Intrathecal
morphine administration is known to reduce peripheral inflam-
matory edema in a nitric oxide dependent mechanism.31 It is
possible that such anti-inflammatory effect may contribute to
the infarct sparing effect of intrathecal morphine in addition to
inducing myocardial adaptation to ischemia.
There are several methodological limitations to this
study that may have implications on the interpretation of the
findings. First, we did not provide direct evidence of neural
involvement by measuring specific nerve activity or by
physically interrupting parts of the nervous system. One of
the difficulties of performing the former is the need to
identify specific nerve fibers responsible, which at this stage
is not known. Further, interrupting autonomic fibers can
cause hemodynamic instability, which could confound the
results. Therefore, we have only provided indirect evidence
of neural involvement. Second, the antagonists used in this
study may have off target effects that may possibly influence
the degree of myocardial damage. For example, GLI may
reduce basal coronary blood flow32 and promotes insulin
release from pancreatic beta cells and may cause hypogly-
cemia. Together these may adversely effects on myocardial
ischemia reperfusion injury. On the other hand, CGRP8–37 is
not known to worsen ischemic injury33 and HOE 140 may
even have a favorable effect.34 Nevertheless, the ISs of the
groups receiving only the antagonists were not different
from the saline CON so any potential increases in IS from
these chemicals may not be significant. Lastly, we did not
rule out any diffusible factor that may have contributed to
the protective effects. Efferent nerve signals may release
substances that may have beneficial effects not only from
nerve terminals but from other organs.
CONCLUSIONS
Myocardial ischemia and or infarction are not
uncommon in the perioperative period35 and, therefore, precon-
ditioning in anticipation of myocardial insult is reasonable. The
advantage of using intrathecal morphine is that it is already in
clinically use, with a well-known risk benefit ratio that is
familiar to clinicians. It has the added advantage of providing
analgesia that may favorably alter the myocardial oxygen sup-
ply and demand balance. We have provided strong indirect
evidence that opioid receptor activation in the spinal cord at
least in part uses a neural pathway to convey its signals to the
periphery for cardioprotection. Intrathecal morphine can acti-
vate similar cellular salvage mechanisms as other experimental
ligands and is, therefore, worthy of further study to determine
any clinical benefit.
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